These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28480267)

  • 1. Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With
    Boix V; Fedorak RN; Mullane KM; Pesant Y; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
    Open Forum Infect Dis; 2017; 4(1):ofw275. PubMed ID: 28480267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.
    Daley P; Louie T; Lutz JE; Khanna S; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
    J Antimicrob Chemother; 2017 Dec; 72(12):3462-3470. PubMed ID: 28961905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
    Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
    J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis.
    Muhammad A; Madhav D; Rawish F; Viveksandeep TC; Albert E; Mollie J; Prateek S
    Curr Clin Pharmacol; 2019; 14(3):166-174. PubMed ID: 30924421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
    Cannon K; Byrne B; Happe J; Wu K; Ward L; Chesnel L; Louie T
    J Antimicrob Chemother; 2017 Dec; 72(12):3453-3461. PubMed ID: 28927227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
    Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of surotomycin for the treatment of Clostridium difficile.
    Knight-Connoni V; Mascio C; Chesnel L; Silverman J
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):195-204. PubMed ID: 26670919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.
    Chandorkar G; Zhan Q; Donovan J; Rege S; Patino H
    BMC Pharmacol Toxicol; 2017 Mar; 18(1):24. PubMed ID: 28347318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
    Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
    Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro.
    Aldape MJ; Rice SN; Field KP; Bryant AE; Stevens DL
    J Med Microbiol; 2018 Dec; 67(12):1689-1697. PubMed ID: 30307842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.
    Adams HM; Li X; Mascio C; Chesnel L; Palmer KL
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4139-47. PubMed ID: 25941217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
    Deshpande A; Hurless K; Cadnum JL; Chesnel L; Gao L; Chan L; Kundrapu S; Polinkovsky A; Donskey CJ
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3333-9. PubMed ID: 26976870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
    Mullane K; Lee C; Bressler A; Buitrago M; Weiss K; Dabovic K; Praestgaard J; Leeds JA; Blais J; Pertel P
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1435-40. PubMed ID: 25534727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
    Guery B; Menichetti F; Anttila VJ; Adomakoh N; Aguado JM; Bisnauthsing K; Georgopali A; Goldenberg SD; Karas A; Kazeem G; Longshaw C; Palacios-Fabrega JA; Cornely OA; Vehreschild MJGT;
    Lancet Infect Dis; 2018 Mar; 18(3):296-307. PubMed ID: 29273269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
    Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH
    J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ; Tillotson GS; Nathan R; Hazan S; Pullman J; Lucasti C; Deck K; Yacyshyn B; Maliakkal B; Pesant Y; Tejura B; Roblin D; Gerding DN; Wilcox MH;
    Lancet Infect Dis; 2017 Jul; 17(7):735-744. PubMed ID: 28461207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.
    Citron DM; Tyrrell KL; Dale SE; Chesnel L; Goldstein EJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2069-74. PubMed ID: 26787687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.
    Endres BT; Bassères E; Khaleduzzaman M; Alam MJ; Chesnel L; Garey KW
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3519-23. PubMed ID: 27021314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.